NeoGenomics to Participate in Upcoming Investor Conferences
Did Narrower Quarterly Loss Just Shift NeoGenomics Stock Investment Narrative?
NEO Q3 deep dive: product mix shift and margin expansion drive robust oncology testing growth
5 revealing analyst questions from NeoGenomics’s Q3 earnings call
NeoGenomics, Inc. 2026 Q3 - Results - Earnings Call Presentation
NeoGenomics (NEO) Beat Q3 Expectations, Is The Stock Still Cheap?
TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $23
BTIG Reiterates Buy on NeoGenomics, Maintains $28 Price Target
What NeoGenomics (NEO) Said on Its Q3 Earnings Call
NeoGenomics (NEO) Q3 2026 Earnings Call Transcript
NeoGenomics (NASDAQ:NEO) Posts In-Line Q3 Revenue and Above-Consensus EPS
NeoGenomics, Inc. (NEO) Q3 2026 Earnings Call Transcript
NeoGenomics: Q3 Earnings Snapshot
NeoGenomics’s (NASDAQ:NEO) Q3 2026 sales beat estimates
NeoGenomics Reports Third Quarter 2026 Results
NeoGenomics Q3 2026 Earnings Call Transcript
NeoGenomics Raises FY2026 Sales Guidance from $802.000M-$806.000M to $807.000M-$809.000M vs $805.827M Est
NeoGenomics Q3 Adj. EPS $0.07 Beats $0.05 Estimate, Sales $209.254M Beat $207.328M Estimate
Earnings to watch: NeoGenomics (NEO) reports Q3 results tomorrow
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.